Scientists, entrepreneurs, and journalists have reached for colorful metaphors to explain CRISPR-Cas9 gene editing technology. Many are really, really bad.
The Food and Drug Administration has approved a promising new treatment called CAR-T for a particularly deadly form of cancer.
Pharmaceutical companies hope computers can help them find new medications that are faster, cheaper-and more likely to be effective.
J uno Therapeutics is abandoning a cancer therapy that once looked like a revolutionary advance, reacting to a rash of patient deaths that made the customized treatment too risky to push forward. The company’s decision changes the landscape in a blockbuster race to commercialize the first CAR-T technology, a promising new approach to cancer in which …